Filing Flows › 13F managers › Regeneron
Regeneron: 13F portfolio Q2 2026 and what copying it returned
Regeneron's 13F for the quarter ended 2026-06-30 (filed Aug 7, 2026): 3 common-share positions, $177M reported. Copying each 13F the day after it was filed returned +1.2% from May 6, 2025 to Nov 6, 2026, against +30.5% for SPY.
Copying the 13F
Each 13F bought at the close of the first trading day after it was filed and held, drifting, until the next one; value-weighted over the common-share positions with a price (99.5% of the portfolio on average); 6 filings since May 2, 2025. Price returns for the clone and SPY alike (no dividends, no costs). A 13F lists only US long positions at quarter end, reported up to 45 days later.
Largest holdings (2026-06-30)
| Ticker | Company | Weight | Value | Change in the quarter |
|---|---|---|---|---|
| PBLS | Parabilis Medicines | 64.3% | $114M | new |
| NTLA | Intellia Therapeutics | 35.4% | $62.7M | unchanged |
| ACET | Adicet Bio | 0.3% | $523K | new |
Biggest adds
- PBLS new
- ACET new
Biggest cuts
- None reported.
Track record
Of 2 position changes scored in 2 separate decisions, 50.0% were on the right side of SPY over the next three months (Disclosures → Smart money).
Open in Disclosures → every quarter, the clone month by month, the smart-money record
Source: SEC Form 13F-HR, filer CIK 872589. Not investment advice.